Lower Insulin Costs; Older Folks Want Obesity Meds Covered; Global Ozempic Woes

More Americans can expect lower insulin costs in 2024 as new $35-a-month price caps are set to go into effect this month. (CNN)

Kids with severe obesity who would eventually go on to undergo bariatric surgery were more likely to be medicated for psychiatric diagnoses than the general population. (The Lancet Child & Adolescent Health)

ASC41, a thyroid hormone receptor β agonist, achieved up to an average 68.2% relative reduction in liver fat content by week 12 in an ongoing phase II trial of adults with biopsy-confirmed non-alcoholic steatohepatitis, said Gannex Pharma.

Over 80% of U.S. adults ages 50 to 80 said Medicare and other insurances should cover weight management medications, according to University of Michigan’s National Poll on Healthy Aging.

Meanwhile, many of these anti-obesity drugs are out of reach for millions of older Americans due to lack of Medicare coverage. (AP)

Taco Bell restaurants that had calorie-labeled menus were associated with an average of 25 fewer calories purchased per transaction than those who left calorie counts off. (JAMA Network Open)

The FDA’s recent warning about counterfeit semaglutide (Ozempic) may be part of a much larger global problem. (NBC News)

Repurposing certain cancer drugs may help regenerate beta cells in people with type 1 diabetes. (Signal Transduction and Targeted Therapy)

The Endocrine Society praised Ohio Gov. Mike DeWine’s (R) veto of a bill that would have banned gender-affirming care for minors.

NeuroBo Pharmaceuticals is looking to initiate a phase I trial of an investigational drug that functions like a GLP-1 receptor agonist and glucagon receptor for the treatment of obesity.

Please enable JavaScript to view the

comments powered by Disqus.